Maat Pharma SA
PAR:MAAT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Maat Pharma SA
Long-Term Debt
Maat Pharma SA
Long-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
M
|
Maat Pharma SA
PAR:MAAT
|
Long-Term Debt
€14.9m
|
CAGR 3-Years
21%
|
CAGR 5-Years
23%
|
CAGR 10-Years
N/A
|
|
|
Valneva SE
PAR:VLA
|
Long-Term Debt
€186.6m
|
CAGR 3-Years
17%
|
CAGR 5-Years
14%
|
CAGR 10-Years
9%
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Long-Term Debt
€3.5m
|
CAGR 3-Years
-63%
|
CAGR 5-Years
-54%
|
CAGR 10-Years
-2%
|
|
|
Inventiva SA
PAR:IVA
|
Long-Term Debt
€51.6m
|
CAGR 3-Years
22%
|
CAGR 5-Years
39%
|
CAGR 10-Years
N/A
|
|
|
DBV Technologies SA
PAR:DBV
|
Long-Term Debt
$5.4m
|
CAGR 3-Years
68%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
N/A
|
|
|
Abivax SA
PAR:ABVX
|
Long-Term Debt
€52.4m
|
CAGR 3-Years
18%
|
CAGR 5-Years
9%
|
CAGR 10-Years
90%
|
|
Maat Pharma SA
Glance View
Maat Pharma SA operates as a clinical-stage microbiome therapeutics company. The company is headquartered in Lyon, Auvergne-Rhone-Alpes and currently employs 43 full-time employees. The company went IPO on 2021-11-08. The firm specializes in the microbiome therapy that is aimed to treatment of Gut Microbiota alteration (Dysbiosis) using patient-specific biotherapeutics in patients with serious medical conditions. Its MaaT Microbiome Restoration Therapy (MMRB) discovery and analysis platform supports the evaluation of drug candidates, the determination of new disease targets and the identification of biomarkers for microbiome-related conditions.
See Also
What is Maat Pharma SA's Long-Term Debt?
Long-Term Debt
14.9m
EUR
Based on the financial report for Dec 31, 2025, Maat Pharma SA's Long-Term Debt amounts to 14.9m EUR.
What is Maat Pharma SA's Long-Term Debt growth rate?
Long-Term Debt CAGR 5Y
23%
Over the last year, the Long-Term Debt growth was 17%. The average annual Long-Term Debt growth rates for Maat Pharma SA have been 21% over the past three years , 23% over the past five years .
